CV screening did not reduce the risk of all-cause death in men 65 to 74 years of age in the DANCAVAS trial, investigators revealed this past weekend at the European Society of Cardiology Congress 2022 ...
Please provide your email address to receive an email when new articles are posted on . In the DANCAVAS trial, an invitation for comprehensive imaging-based CV screening did not significantly lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results